Overview

The Super Human Blend combines two categories of peptides: growth hormone secretagogues (CJC-1295 + Ipamorelin) and tissue repair peptides (BPC-157 + TB-500). Each pair has established synergy within its category, and the combination protocol seeks to leverage cross-category benefits -- using GH axis stimulation to amplify the healing effects of tissue repair peptides, while the repair peptides support the structural recovery needed to benefit fully from GH-mediated anabolism.

CJC-1295 stimulates growth hormone release from the pituitary by activating GHRH receptors, while Ipamorelin acts through the ghrelin/GHS receptor pathway. Together, they produce amplified GH pulses through dual-receptor activation. BPC-157 promotes angiogenesis and fibroblast recruitment via VEGFR2 signaling, while TB-500 enhances cell migration through actin regulation. Together, they address both vascular supply and cellular mobilization components of wound healing.

This blend is available through compounding pharmacies as either a pre-mixed vial or as separate vials to be combined by the end user. No clinical trials have evaluated the specific four-peptide combination, and the rationale rests on the established mechanisms and preclinical data for each component individually and in pairs.

Mechanism of Action

GH Secretagogue Component

• CJC-1295 (GHRH pathway): Binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and secretion through cAMP-PKA signaling. Provides the "release signal" for GH synthesis and pulse initiation
• Ipamorelin (GHS-R1a pathway): Activates ghrelin receptors on the pituitary and hypothalamus, amplifying GH pulses through phospholipase C / calcium signaling. Suppresses somatostatin release, extending GH pulse duration. Selective for GH release -- does not significantly elevate cortisol, ACTH, or prolactin unlike GHRP-6 or GHRP-2

Tissue Repair Component

• BPC-157 (angiogenesis/VEGFR2): Upregulates VEGFR2 expression and stimulates fibroblast proliferation and migration, promoting angiogenesis and extracellular matrix deposition at injury sites
• TB-500 (cell migration/actin): Sequesters G-actin monomers to regulate F-actin polymerization, facilitating cell migration and tissue repair through enhanced motility of fibroblasts, endothelial cells, and immune cells

Cross-Category Synergy

The GH secretagogue and tissue repair components may interact synergistically through several mechanisms:

• GH and IGF-1 elevation amplifies fibroblast proliferation and collagen synthesis, potentially enhancing BPC-157 and TB-500's repair effects
• BPC-157 upregulates growth hormone receptor expression on fibroblasts (Chang et al., 2014), potentially increasing tissue responsiveness to the GH/IGF-1 elevated by CJC-1295/Ipamorelin
• TB-500 provides the actin-dependent cell migration infrastructure needed for GH receptor-expressing fibroblasts to reach wound sites

Reconstitution Calculator

Research

Safety Profile

The safety profile of the Super Human Blend is based on the individual components, as no formal safety studies exist for the four-peptide combination:

• CJC-1295: Flushing, headache, dizziness at injection time (transient). Theoretical concerns about sustained IGF-1 elevation with chronic use.
• Ipamorelin: Generally well-tolerated. Transient headache, flushing. Minimal effect on cortisol and prolactin (advantage over GHRP-2/GHRP-6).
• BPC-157: No reported toxicity in preclinical studies across wide dose ranges. No human clinical trial safety data.
• TB-500: Limited safety data. Theoretical concerns about proliferative effects in the context of active malignancy.
• Combined: No drug interaction data for the four-peptide combination. The shared GH-stimulatory and angiogenic properties raise theoretical concerns that have not been formally evaluated.
• Compounding quality: As a compounded product, stability and purity depend on the compounding pharmacy's practices.

Pharmacokinetic Profile